Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pathogenic germline variants in patients with breast cancer: conversations across generations, practices and patients' attitude.
Abdel-Razeq H, Mustafa R, Abdel-Razeq S, Abu-Fares H, Al Masri S, Damsees R, El-Atrash M, Elemian S, Alkyam M, Ammar K, Bater R, Kderat M, Alhajahjeh A. Abdel-Razeq H, et al. Among authors: abu fares h. Front Genet. 2023 Oct 18;14:1194075. doi: 10.3389/fgene.2023.1194075. eCollection 2023. Front Genet. 2023. PMID: 37920853 Free PMC article.
Differences in Treatment Outcomes Between Patients with HER2-Low versus HER2-Zero, Hormone Receptor-Positive Advanced-Stage Breast Cancer Treated with Ribociclib.
Sharaf B, Abu-Fares H, Tamimi F, Al-Sawajneh S, Salama O, Daoud R, Alhajahjeh A, Al-Lababidi S, Abdel-Razeq H. Sharaf B, et al. Among authors: abu fares h. Breast Cancer (Dove Med Press). 2023 Jul 28;15:541-548. doi: 10.2147/BCTT.S415432. eCollection 2023. Breast Cancer (Dove Med Press). 2023. PMID: 37533590 Free PMC article.
COMPASS-CAT versus Khorana risk assessment model for predicting venous thromboembolic events in patients with non-small cell lung cancer on active treatment with chemotherapy and/or immunotherapy, the CK-RAM study.
Abdel-Razeq H, Sharaf B, Al-Jaghbeer MJ, Abu-Fares H, Bater R, Shaer MA, Abu-Jaish H, Laban DA, Salamah O, Tamimi F, Ashouri K, Salameh T, Zughul R, Alhalaseh Y. Abdel-Razeq H, et al. Among authors: abu fares h. J Thromb Thrombolysis. 2023 Oct;56(3):447-453. doi: 10.1007/s11239-023-02860-4. Epub 2023 Jul 11. J Thromb Thrombolysis. 2023. PMID: 37430158
Guideline-Based, Multi-Gene Panel Germline Genetic Testing for at-Risk Patients with Breast Cancer.
Abdel-Razeq H, Abujamous L, Al-Azzam K, Abu-Fares H, Bani Hani H, Alkyam M, Sharaf B, Elemian S, Tamimi F, Abuhijla F, Edaily S, Salama O, Abdulelah H, Daoud R, Abubaker M, Al-Atary A. Abdel-Razeq H, et al. Among authors: abu fares h. Breast Cancer (Dove Med Press). 2023 Jan 13;15:1-10. doi: 10.2147/BCTT.S394092. eCollection 2023. Breast Cancer (Dove Med Press). 2023. PMID: 36660366 Free PMC article.
Prevalence and clinical implications of germline mutations among Jordanian patients with ovarian cancer. The Jordanian exploratory cancer genetics (Jo-ECAG) ovarian study.
Abdel-Razeq H, Al-Azzam K, Elemian S, Abu-Fares H, Abu Sheikha A, Bani Hani H, Bater R, Sharaf B, Heald B, Esplin ED, Nielsen SM, Alkyam M, Abujamous L, Al-Attary A. Abdel-Razeq H, et al. Among authors: abu fares h. Mol Genet Genomic Med. 2023 Apr;11(4):e2125. doi: 10.1002/mgg3.2125. Epub 2022 Dec 19. Mol Genet Genomic Med. 2023. PMID: 36537080 Free PMC article.